JanOne Inc. (JAN) News
Filter JAN News Items
JAN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest JAN News From Around the Web
Below are the latest news stories about JANONE INC that investors may wish to consider to help them evaluate JAN as an investment opportunity.
Why Is Assertio (ASRT) Stock Down 39% Today?Assertio stock is dropping on Thursday as investors in ASRT react to the company's poor earnings results for the third quarter of 2023. |
Why Is Atara Biotherapeutics (ATRA) Stock Down 50% Today?Atara Biotherapeutics stock is falling on Thursday as investors in ATRA react to the company's latest Phase 2 clinical trial data. |
Why Is JanOne (JAN) Stock Up 40% Today?JanOne stock is climbing higher on Thursday with heavy trading of JAN shares despite a lack of news from the biopharmaceutical company. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayIt's time to start the day with a breakdown of the biggest pre-market stock movers worth keeping tabs on for Thursday morning! |
JanOne to Present at the Dawson James 8th Annual Investment ConferenceJanOne (Nasdaq: JAN), the biopharmaceutical company focused on developing non-addicting painkillers and novel treatments for the causes of pain, will participate in investor sessions at the Dawson James Securities 8th Annual Investment Conference in Jupiter, Florida. JanOne's Chief Medical Officer, Dr. Amol Soin, will attend the October 12, day-long conference and present JanOne's mission and progress. |
Dawson James Securities Announces October Date for 8th Annual Small Cap Growth ConferenceJUPITER, Fla., Sept. 21, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- Dawson James Securities, Inc. (“Dawson”), a full-service investment bank focused on emerging growth companies, today announces its 8th Annual Dawson James Small Cap Growth Conference on October 12, 2023, at the Wyndham Grand Hotel in Jupiter, FL. Dawson James’ flagship Small Cap Growth Conference brings together senior leadership from over 30 of the most innovative companies at the forefront of healthcare, technology and consu |
JanOne to Present In Person and by Video at H.C. Wainwright's 25th Annual Global Investment ConferenceJanOne (Nasdaq: JAN), the biopharmaceutical company focused on developing non-addicting painkillers and novel treatments for the causes of pain, will participate in investor sessions at the H.C. Wainwright 25th Annual Global Investment Conference in New York City. JanOne's Chief Medical Officer, Dr. Amol Soin, will appear via recorded video and attend the conference in person to represent the company's mission and progress. |
JanOne Earns US Patent for the Use of its Novel Formulation of Low-Dose Naltrexone, Jan123, to Treat Chronic PainJanOne (Nasdaq: JAN), the visionary biotech company dedicated to discovering non-addictive treatments for pain, as well as causes of pain, has earned a US patent for its innovative formulation of low-dose naltrexone, Jan123, for treating pain. |
JanOne Wins "Best Abstract" Award at the Ohio Society of Interventional Pain Physicians Annual MeetingJanOne (Nasdaq: JAN), the biopharmaceutical company focused on developing non-addicting painkillers and novel treatments for the causes of pain, has won a prestigious "Best Abstract" award for reporting that JanOne's treatment for diabetic neuropathy showed both effectiveness against pain and potential to improve nerve function. |
JanOne Technologies Announces Closing of Registered Direct Offering Priced At-The-Market under Nasdaq RulesJanOne (Nasdaq: JAN) (the "Company"), a biopharmaceutical company specializing in developing non-addicting pain killers and treatments for underlying causes of pain, today announced that it has closed its previously announced registered direct offering for the purchase and sale of 899,348 shares of the Company's common stock (or prefunded warrants in lieu thereof) at a purchase price of $0.8811 per share of common stock (or prefunded warrant) in a registered direct offering priced at-the-market |